GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Cash Ratio

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Cash Ratio : 0.03 (As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. IntelliPharmaCeutics International's Cash Ratio for the quarter that ended in Aug. 2023 was 0.03.

IntelliPharmaCeutics International has a Cash Ratio of 0.03. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for IntelliPharmaCeutics International's Cash Ratio or its related term are showing as below:

IPCIF' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.15   Max: 1.9
Current: 0.03

During the past 13 years, IntelliPharmaCeutics International's highest Cash Ratio was 1.90. The lowest was 0.01. And the median was 0.15.

IPCIF's Cash Ratio is ranked worse than
96.19% of 1524 companies
in the Biotechnology industry
Industry Median: 2.92 vs IPCIF: 0.03

IntelliPharmaCeutics International Cash Ratio Historical Data

The historical data trend for IntelliPharmaCeutics International's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cash Ratio Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.25 0.01 0.02 0.08 0.01

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.03

Competitive Comparison of IntelliPharmaCeutics International's Cash Ratio

For the Biotechnology subindustry, IntelliPharmaCeutics International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Cash Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Cash Ratio falls into.



IntelliPharmaCeutics International Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

IntelliPharmaCeutics International's Cash Ratio for the fiscal year that ended in Nov. 2022 is calculated as:

Cash Ratio (A: Nov. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.084/12.009
=0.01

IntelliPharmaCeutics International's Cash Ratio for the quarter that ended in Aug. 2023 is calculated as:

Cash Ratio (Q: Aug. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.4/14.442
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


IntelliPharmaCeutics International Cash Ratio Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.